[go: up one dir, main page]

MA56541A - Plateformes, compositions et méthodes d'administration de composés thérapeutiques - Google Patents

Plateformes, compositions et méthodes d'administration de composés thérapeutiques

Info

Publication number
MA56541A
MA56541A MA056541A MA56541A MA56541A MA 56541 A MA56541 A MA 56541A MA 056541 A MA056541 A MA 056541A MA 56541 A MA56541 A MA 56541A MA 56541 A MA56541 A MA 56541A
Authority
MA
Morocco
Prior art keywords
platforms
compositions
methods
therapeutic compounds
delivering therapeutic
Prior art date
Application number
MA056541A
Other languages
English (en)
Inventor
Milad Riazifar
Todd Schurr
Charles Cameron Taylor
Original Assignee
Entelexo Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entelexo Biotherapeutics Inc filed Critical Entelexo Biotherapeutics Inc
Publication of MA56541A publication Critical patent/MA56541A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA056541A 2019-06-21 2020-06-19 Plateformes, compositions et méthodes d'administration de composés thérapeutiques MA56541A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962864566P 2019-06-21 2019-06-21
US201962875001P 2019-07-17 2019-07-17

Publications (1)

Publication Number Publication Date
MA56541A true MA56541A (fr) 2022-04-27

Family

ID=74037053

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056541A MA56541A (fr) 2019-06-21 2020-06-19 Plateformes, compositions et méthodes d'administration de composés thérapeutiques

Country Status (9)

Country Link
US (2) US20220112264A1 (fr)
EP (1) EP3986429A4 (fr)
JP (2) JP2022537807A (fr)
CN (1) CN114269360A (fr)
AU (1) AU2020298314A1 (fr)
CA (1) CA3144267A1 (fr)
IL (1) IL289114A (fr)
MA (1) MA56541A (fr)
WO (1) WO2020257710A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102771126B1 (ko) * 2019-04-19 2025-02-20 후지필름 가부시키가이샤 세포 외 소포의 보존 안정화제 및 보존 안정화 방법
MA56541A (fr) 2019-06-21 2022-04-27 Entelexo Biotherapeutics Inc Plateformes, compositions et méthodes d'administration de composés thérapeutiques
WO2021159016A1 (fr) * 2020-02-05 2021-08-12 Diadem Biotherapeutics Inc. Synapses artificielles
EP4111166B1 (fr) 2020-02-24 2024-11-20 Corning Incorporated Ensemble d'étalonnage comprenant des nanoparticules de nylon-6 et des colorants
BR112022026309A2 (pt) 2020-06-24 2023-01-17 Chameleon Biosciences Inc Vesículas extracelulares com moduladores imune
US20230190818A1 (en) * 2020-07-09 2023-06-22 Exo Biologics Sa Process for the Manufacturing of Protein-Associated Extracellular Vesicles
WO2022133301A1 (fr) * 2020-12-18 2022-06-23 Entelexo Biotherapeutics, Inc. Plateformes, compositions et méthodes pour administration thérapeutique
EP4023231A1 (fr) * 2020-12-29 2022-07-06 Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana Vésicules extracellulaires dérivées de cellules stromales mésenchymateuses génétiquement modifiées pour la surexpression hif-1a et htert
CN112575005A (zh) * 2021-01-04 2021-03-30 昆明理工大学 一种提高烟草重金属镉胁迫抗性和降低镉富集的方法
US20220218755A1 (en) * 2021-01-11 2022-07-14 United Therapeutics Corporation Extracellular vesicles and their uses
US20230277595A1 (en) * 2021-02-22 2023-09-07 Rohto Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent for diabetes
CN113521101A (zh) * 2021-05-20 2021-10-22 广州医科大学附属第一医院（广州呼吸中心） 干细胞来源的外泌体在制备治疗慢性阻塞性肺疾病药物中的应用
CN113769106A (zh) * 2021-08-13 2021-12-10 深圳湾实验室 用于肿瘤免疫治疗的融合细胞膜纳米囊泡、其制备方法及应用
WO2023076418A2 (fr) * 2021-10-26 2023-05-04 Entelexo Biotherapeutics, Inc. Plates-formes, compositions et méthodes d'administration thérapeutique
EP4512903A3 (fr) * 2021-12-03 2025-07-02 China Medical University Production d'exosomes et leurs utilisations
CN114107253B (zh) * 2021-12-17 2024-03-15 复旦大学附属华山医院 一种利用工程细胞进行基因编辑的系统及方法
WO2024000263A1 (fr) * 2022-06-29 2024-01-04 Beijing Thera Bioscience Co., Ltd. Procédés de fabrication et d'utilisation de vésicules extracellulaires
TWI895950B (zh) * 2023-01-30 2025-09-01 中國醫藥大學 外泌體、其製備方法、其用途以及醫藥組合物
JP7730003B2 (ja) * 2023-02-10 2025-08-27 中国▲医▼薬大学 細胞外小胞／エクソソーム保存溶液及びその混合溶液
CN118526597A (zh) * 2023-02-23 2024-08-23 厦门大学 Lrrk2抑制剂在抗肿瘤中的应用
CN117024557B (zh) * 2023-10-10 2024-01-30 天津外泌体科技有限公司 14-3-3蛋白theta异构体作为细胞外囊泡支架蛋白的应用和细胞外囊泡
WO2025101988A1 (fr) * 2023-11-09 2025-05-15 Nutech Ventures Petites vésicules extracellulaires modifiées et leurs utilisations
WO2025147583A1 (fr) * 2024-01-05 2025-07-10 Sail Biomedicines, Inc. Ligands pd-1 modifiés
WO2025174637A1 (fr) * 2024-02-15 2025-08-21 The Trustees Of Indiana University Procédés de détection et utilisations de pd-l1
CN120290490A (zh) * 2025-06-06 2025-07-11 山东省第二人民医院(山东省耳鼻喉医院、山东省耳鼻喉研究所) 过表达cd24的工程化外泌体递药系统及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
JP6542197B2 (ja) * 2013-04-12 2019-07-10 エヴォックス・セラピューティクス・リミテッド 治療的送達小胞
HK1255328A1 (zh) * 2015-06-30 2019-08-16 纳米提克斯有限责任公司 与清除颗粒相关的组合物和方法
US11090385B2 (en) * 2015-12-21 2021-08-17 Gholam A. Peyman Early cancer detection and enhanced immunotherapy
EP3402489B1 (fr) * 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Compositions d'exosomes à base de sdc2 et leurs procédés d'isolement et d'utilisation
WO2017176762A1 (fr) * 2016-04-06 2017-10-12 Nanotics, Llc Particules comprenant des sous-particules ou des échafaudages d'acide nucléique
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018075825A1 (fr) 2016-10-19 2018-04-26 Northwestern University Diagnostics basés sur les vésicules extracellulaires et exosomes modifiés pour une thérapie ciblée contre le cancer
WO2018129207A1 (fr) * 2017-01-04 2018-07-12 Nanotics, Llc Procédés d'assemblage de particules éliminatrices
US20200392219A1 (en) * 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
US11692172B2 (en) * 2017-06-26 2023-07-04 Mackay Memorial Hosptal Formulation comprising extracellular vesicles, method for producing the same, and uses thereof
US11938219B2 (en) * 2017-07-29 2024-03-26 University Of Southern California Synthetic extracellular vesicles for novel therapies
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
GB201718681D0 (en) * 2017-11-13 2017-12-27 Evox Therapeutics Ltd Protein engineered extracellular vesicles
CN108103026B (zh) * 2017-12-05 2020-12-22 四川省肿瘤医院 用于肿瘤免疫治疗的γδ-T细胞外泌体及其制备方法
MA56541A (fr) 2019-06-21 2022-04-27 Entelexo Biotherapeutics Inc Plateformes, compositions et méthodes d'administration de composés thérapeutiques
AU2020390448A1 (en) 2019-11-28 2022-07-14 Mcmaster University Recombinant polypeptides for programming extracellular vesicles
WO2022133301A1 (fr) 2020-12-18 2022-06-23 Entelexo Biotherapeutics, Inc. Plateformes, compositions et méthodes pour administration thérapeutique

Also Published As

Publication number Publication date
AU2020298314A1 (en) 2022-02-03
CA3144267A1 (fr) 2020-12-24
US20220389078A1 (en) 2022-12-08
CN114269360A (zh) 2022-04-01
EP3986429A4 (fr) 2023-07-19
WO2020257710A1 (fr) 2020-12-24
US20220112264A1 (en) 2022-04-14
JP2025174969A (ja) 2025-11-28
JP2022537807A (ja) 2022-08-30
EP3986429A1 (fr) 2022-04-27
IL289114A (en) 2022-02-01
US11851470B2 (en) 2023-12-26

Similar Documents

Publication Publication Date Title
MA56541A (fr) Plateformes, compositions et méthodes d'administration de composés thérapeutiques
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
PH12020550341A1 (en) Niraparib formulations
EP3310343A4 (fr) Compositions implantables pour administration de médicaments et méthodes d'utilisation desdites compositions
EP3857228A4 (fr) Composés, compositions et méthodes d'amélioration de dosages
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
EP3402480A4 (fr) Compositions et méthodes d'administration par intraveineuse de 2-bromo-1-(3,3-dinitroazétidine-1-yl)éthanone
EP3817747A4 (fr) Administration ciblée d'agents thérapeutiques à des adipocytes humains
EP4028059A4 (fr) Compositions médicinales stables de cannabidiol
EP4297784A4 (fr) Compositions et méthodes d'administration thérapeutique
EP3917528A4 (fr) Administration ciblée de phlip® de composés cytotoxiques puissants
TN2017000158A1 (en) Carbazole derivatives
EP3921420A4 (fr) Compositions d'administration de médicament pour l'administration oculaire d'agents thérapeutiques et leurs méthodes d'utilisation
EP3917971A4 (fr) Administration intracellulaire médiée par phlip® de composés immunostimulateurs
EP4100539A4 (fr) Variants adéno-associés, formulations et méthodes d'administration pulmonaire
MX2020007731A (es) Compuestos moduladores de receptor de estrogeno.
EP3713569A4 (fr) Compositions et méthodes d'administration d'une composition inhibitrice d'yap1/wwrt1 et d'une composition inhibitrice de gls1
MA52200A (fr) Compositions de vaa, procédés de préparation et méthodes d'utilisation
EP3917910A4 (fr) Composés et compositions thérapeutiques
EP3768242A4 (fr) Méthodes et compositions pour l'administration ciblée d'agents actifs et d'agents immunomodulateurs à des ganglions lymphatiques
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها